J&J Covid vaccine manufacturing halted at plant that ruined doses

accreditation
0:00
play article
Subscribers can listen to this article
  • The pharmaceutical giant told AFP at the end of March it had identified a batch of ruined doses at a plant in Baltimore.
  • 15 million doses were reportedly in that batch.
  • Europe's medicines regulator is expected to rule on Tuesday on the J&J vaccine's safety, after its European use was also put on hold over blood clot fears.

The US Food and Drug Administration requested that production of the Johnson & Johnson coronavirus vaccine be halted at a factory that previously reportedly ruined about 15 million doses of the shot.

The pharmaceutical giant told AFP at the end of March it had identified a batch of doses at a plant in Baltimore run by Emergent BioSolutions "that did not meet quality standards," but did not confirm the specific number affected.

The New York Times later reported the batch consisted of about 15 million doses.

Emergent BioSolutions said in a regulatory Securities and Exchange Commission filing on Monday that the FDA had requested a pause on April 16 in production of the single-shot vaccine pending an inspection at the Baltimore, Maryland facility.

READ HERE | How worried should we be about blood clots

"On April 16, 2021, at the request of the FDA, Emergent agreed not to initiate the manufacturing of any new material at its Bayview facility and to quarantine existing material manufactured at the Bayview facility pending completion of the inspection and remediation of any resulting findings," the filing said.

Johnson & Johnson had said in March it was sending more experts to the site to oversee vaccine production, and that it expected to deliver 24 million additional shots through April.

The Emergent BioSolutions plant had not been authorized by US regulators at the time to manufacture a "drug substance" for the J&J vaccine, the pharmaceutical company said, but US media reported that it was expected to produce tens of millions of doses in the near future.

READ | US may need 2 weeks to determine if J&J shot causes extremely rare blood clots

The J&J vaccine won praise for its single dosage and because it does not need to be frozen - unlike the shots from Moderna and Pfizer - making distribution much simpler.

The manufacturing pause is the latest setback for the vaccine in the United States, as regulators temporarily halted its use after authorities reported six cases of women developing blood clots along with low blood platelet counts, including one death, within two weeks of getting the J&J shot.

Europe's medicines regulator is expected to rule on Tuesday on the J&J vaccine's safety, after its European use was also put on hold over blood clot fears.


Did you know you can comment on this article? Subscribe to News24 and add your voice to the conversation.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
Matric results are out! Are you happy with your child's result?
Please select an option Oops! Something went wrong, please try again later.
Results
No, the pandemic really messed up their ability to focus
24% - 17 votes
Yes, they did well given the circumstances
76% - 53 votes
Vote
Rand - Dollar
15.13
+0.8%
Rand - Pound
20.52
+1.0%
Rand - Euro
17.15
+0.5%
Rand - Aus dollar
10.88
+1.2%
Rand - Yen
0.13
+0.4%
Gold
1,835.44
-0.2%
Silver
24.38
-0.4%
Palladium
2,086.50
+0.9%
Platinum
1,033.50
-0.9%
Brent Crude
88.38
-0.1%
Top 40
68,208
-2.0%
All Share
74,886
-1.8%
Resource 10
74,900
-3.0%
Industrial 25
94,240
-1.7%
Financial 15
15,089
-0.2%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE